SYNGR3 and HIV infectious disease: Blocking the interaction between Syn2a and Syngr3 by a BBB-permeable peptide, or Ritonavir, an FDA-approved drug for HIV infection, effectively preserves the E/I balance of BLA and improves fear extinction (Figure 9).